Cargando…
Acute anterior uveitis after discontinuation of tocilizumab in a patient with rheumatoid arthritis
BACKGROUND: Tocilizumab is a humanized monoclonal anti-interleukin-6 (IL-6) receptor antibody and has been approved in Japan for the treatment of Castleman’s disease, rheumatoid arthritis (RA), and systemic juvenile idiopathic arthritis. Conjunctivitis and dry eye are known ocular adverse effects, b...
Autores principales: | Sato, Tomohito, Minakuchi, Shinya, Mochizuki, Manabu, Takeuchi, Masaru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3891663/ https://www.ncbi.nlm.nih.gov/pubmed/24531503 http://dx.doi.org/10.2147/OPTH.S54929 |
Ejemplares similares
-
Methotrexate Discontinuation and Dose Decreases After Therapy With Tocilizumab: Results From the Corrona Rheumatoid Arthritis Registry
por: Pappas, Dimitrios A., et al.
Publicado: (2020) -
Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study)
por: Kaneko, Yuko, et al.
Publicado: (2018) -
Successful treatment of Behçet’s uveitis with Tocilizumab
por: Alokaily, F., et al.
Publicado: (2017) -
Topical Corticosteroid-Resolved Rubeosis Iridis with Neovascular Glaucoma Caused by Noninfectious Granulomatous Uveitis
por: Sora, Daisuke, et al.
Publicado: (2018) -
Acute Generalized Exanthematous Pustulosis due to Tocilizumab in a Rheumatoid Arthritis Patient
por: Izquierdo, J. H., et al.
Publicado: (2012)